Cord Blood America Updates Corporate Profile for Brokers, Investors

Wednesday, March 17, 2010 Corporate News J E 4

LAS VEGAS, March 17 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company ( ), focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced its has produced a new edition of Corporate Profile, which is used to answer inquiries about the Company from brokers, investors and other interested individuals.

The Corporate Profile is available at

"The Corporate Profile carefully details the Company's Overview, Business Strategies and Products. It gives details on the Corporate Management and Recent Accomplishments and provides financial and other details about the Company and outlines its Mission, We recommend it for anyone doing due diligence on Cord Blood America," said Matthew Schissler, co-founder and CEO.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at For investor information, visit

CONTACT: Paul Knopick E & E Communications 949/707-5365

SOURCE Cord Blood America, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
PAREXEL Completes Early Phase Study Requiring Geno...
Hikma 2009 Results Interviews With CEO and CFO